All rare diseases articles
-
BusinessAstraZeneca to buy rare disease drugmaker Alexion in $39bn deal
Transaction would be the largest in AstraZeneca’s history
-
BusinessCancer and rare diseases dominated 2019 drug approvals
More streamlined review processes and changing R&D priorities have contributed to sustained increase in new medicines
-
BusinessPharmaceuticals roundup 2019
Under the shadow of political turmoil and major lawsuits, the industry returned to its strengths – making new drugs, and finding new ways to do it better
-
ArticlePharma and healthcare meets data and digitalisation
UK-based company Life Science Integrates exists to facilitate collaboration between digital, pharma and life sciences industries – helping form partnerships that revolutionise healthcare
-
BusinessTakeda set to swallow Shire
Shire’s US revenue and rare diseases portfolio grab Japanese firm’s attention
-
BusinessSanofi enters M&A bonanza
French drugmaker strengthens rare diseases portfolio with blood disorder purchases
-
BusinessTargeting rare diseases
Is working on genetic mutations that affect only a few in every thousand people risky?
-
ResearchError-free next-generation DNA sequencing pioneered
Algorithmic fix allows ultra-accurate sequencing of rare cancers and genetic conditions
-
ReviewOutbreak! 50 tales of epidemics that terrorized the world
A tour of history’s most devastating diseases
-
BusinessShire bets big on rare diseases
$32bn Baxalta buyout will deepen Shire’s commitment to developing specialist drugs for small patient populations
-
FeatureCombating rare diseases
Developing drugs for treating rare diseases isn’t always financially viable. Clare Sansom looks at some recent success stories
-
News
US ramps up rare diseases research
National Institutes of Health spends $29 million to study more than 200 rare diseases
-
Business
Shire will cut UK R&D to focus on rare diseases
$4.2bn buyout of ViroPharma bolsters pipeline, while Basingstoke site halts research
-
NewsOrphan drugs set for 'tremendous growth'
Drugs for rare diseases are rapidly becoming very profitable with growth predicted to outstrip non-orphan drugs
-
Business
Myelofibrosis drug approved in EU
Jakavi (ruxolitinib) tablets are for the treatment of myelofibrosis, a rare disease affecting the bone marrow